| Asembo 2005 | Gem 2005 | Asembo 2002 | Gem 2002 |
---|---|---|---|---|
Services | n (%) | n (%) | n (%) | n (%) |
Palpation of abdomen | 238/241 (98.8) | 381/384 (99.2) | 290/292 (99.3) | 272/278 (97.8) |
Listen to foetal heart rate | 233/241 (96.7) | 377/384 (98.2) | NA | NA |
Tetanus vaccination | 232/242 (95.9) | 361/382 (94.5) | 282/292 (96.6) | 273/278 (98.2) |
Weight measurement | 191/241 (79.3)* | 377/384 (98.2) | 241/293 (82.3)* | 277/278 (99.6) |
Iron supplementation | 197/239 (82.4)* | 260/373 (69.7) | 154/289 (53.3) | 149/277 (53.8) |
Folic acid supplementation | 167/232 (72.0)* | 170/356 (47.8) | 153/290 (52.8)* | 100/269 (37.2) |
SP ≥ 1 dose | 148/240 (61.7)* | 74/373 (19.8) | 58/286 (20.3) | 63/277 (22.7) |
SP ≥ 2 doses | 67/237 (28.3)* | 14/370 (3.8) | 22/237 (9.3) | 20/357 (5.6) |
Blood pressure measurement | 152/240 (63.3)* | 274/384 (71.4) | 198/292 (67.8) | 187/276 (67.8) |
Test haemoglobin level | 72/237 (30.8) | 144/377 (38.2) | 148/286 (51.8) | 138/274 (48.5) |
Urine analysis done | 73/240 (30.4)* | 88/383 (23.0) | 59/293 (20.1)* | 30/278 (10.8) |
Stool test | 58/240 (24.2)* | 45/384 (11.7) | 50/293 (17.1)* | 22/278 (7.9) |
Antihelminth treatment | 30/237 (12.7)* | 15/365 (4.1) | 13/283 (4.6)* | 2/268 (0.8) |
Offered test for STD (e.g. syphilis) | 20/232 (8.6) | 45/377 (11.9) | 62/289 (21.5) | 49/277 (17.7) |
Offered test for HIV | 26/232 (11.2)* | 139/379 (36.7) | NA | NA |
Health talk provided | 42/240 (17.5)* | 115/382 (30.1) | 45/289 (15.6) | 35/278 (12.6) |
Information provided on: | Â | Â | Â | Â |
   Danger signs in pregnancy | 25/241 (10.4) | 44/376 (11.7) | 49/291 (16.8) | 33/276 (12.0) |
   Malaria in pregnancy | 58/241 (24.0) | 83/381 (21.8) | NA | NA |
   Birth plan discussed | 33/241 (13.7)* | 80/380 (21.1) | NA | NA |
   Danger signs during delivery | 17/241 (7.1) | 37/380 (9.7) | NA | NA |
   Danger signs after delivery | 11/240 (4.6) | 33/381 (8.7) | NA | NA |
   Breastfeeding | 36/240 (15.0)* | 85/383 (22.2) | NA | NA |
   Family planning | 18/240 (7.5)* | 97/383 (25.3) | NA | NA |